Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.

The impact of previous SARS-CoV-2 infection on the durability of Ad26.COV2.S vaccine-elicited responses, and the effect of homologous boosting has not been well explored. We followed a cohort of healthcare workers for 6 months after receiving the Ad26.COV2.S vaccine and a further one month after the...

Full description

Saved in:
Bibliographic Details
Main Authors: Thandeka Moyo-Gwete, Simone I Richardson, Roanne Keeton, Tandile Hermanus, Holly Spencer, Nelia P Manamela, Frances Ayres, Zanele Makhado, Thopisang Motlou, Marius B Tincho, Ntombi Benede, Amkele Ngomti, Richard Baguma, Masego V Chauke, Mathilda Mennen, Marguerite Adriaanse, Sango Skelem, Ameena Goga, Nigel Garrett, Linda-Gail Bekker, Glenda Gray, Ntobeko A B Ntusi, Catherine Riou, Wendy A Burgers, Penny L Moore
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-11-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1011772
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.ppat.1011772

Similar Items